GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orchid Pharma Ltd (NSE:ORCHPHARMA) » Definitions » EV-to-Revenue

Orchid Pharma (NSE:ORCHPHARMA) EV-to-Revenue : 6.74 (As of May. 03, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Orchid Pharma EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Orchid Pharma's enterprise value is ₹54,723 Mil. Orchid Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ₹8,122 Mil. Therefore, Orchid Pharma's EV-to-Revenue for today is 6.74.

The historical rank and industry rank for Orchid Pharma's EV-to-Revenue or its related term are showing as below:

NSE:ORCHPHARMA' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.05   Med: 1.99   Max: 24.4
Current: 6.74

During the past 13 years, the highest EV-to-Revenue of Orchid Pharma was 24.40. The lowest was 0.05. And the median was 1.99.

NSE:ORCHPHARMA's EV-to-Revenue is ranked worse than
82.44% of 1025 companies
in the Drug Manufacturers industry
Industry Median: 2.36 vs NSE:ORCHPHARMA: 6.74

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-03), Orchid Pharma's stock price is ₹1059.55. Orchid Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₹176.94. Therefore, Orchid Pharma's PS Ratio for today is 5.99.


Orchid Pharma EV-to-Revenue Historical Data

The historical data trend for Orchid Pharma's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orchid Pharma EV-to-Revenue Chart

Orchid Pharma Annual Data
Trend Mar12 Mar13 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.92 1.03 23.29 2.54 2.81

Orchid Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.35 2.81 3.55 3.73 4.46

Competitive Comparison of Orchid Pharma's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Orchid Pharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orchid Pharma's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orchid Pharma's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Orchid Pharma's EV-to-Revenue falls into.



Orchid Pharma EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Orchid Pharma's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=54723.142/8121.669
=6.74

Orchid Pharma's current Enterprise Value is ₹54,723 Mil.
Orchid Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹8,122 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orchid Pharma  (NSE:ORCHPHARMA) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Orchid Pharma's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1059.55/176.943
=5.99

Orchid Pharma's share price for today is ₹1059.55.
Orchid Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹176.94.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orchid Pharma EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Orchid Pharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Orchid Pharma (NSE:ORCHPHARMA) Business Description

Traded in Other Exchanges
Address
313, Valluvarkottam High Road, Orchid Towers, Nungambakkum, Chennai, TN, IND, 600 034
Orchid Pharma Ltd is involved in the development, manufacturing, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company operates in one business segment which is Pharmaceutical Products. The company produces various products for cardiovascular, anti-diabetic, neuropsychiatry, veterinary, non-antibiotics, and cephalosporins. The products are grouped under formulations and active pharmaceutical ingredients. The company operates its business throughout the Indian region.

Orchid Pharma (NSE:ORCHPHARMA) Headlines

No Headlines